Promising role of peroxisome proliferator-activated receptors in respiratory disorders, a review.

IF 3.8 2区医学 Q2 PHARMACOLOGY & PHARMACY Drug Metabolism Reviews Pub Date : 2025-02-01 Epub Date: 2024-12-26 DOI:10.1080/03602532.2024.2442012

Sima Beigoli, Sahar Kiani, Fereshteh Asgharzadeh, Arghavan Memarzia, Mohammad Hossein Boskabady

{"title":"Promising role of peroxisome proliferator-activated receptors in respiratory disorders, a review.","authors":"Sima Beigoli, Sahar Kiani, Fereshteh Asgharzadeh, Arghavan Memarzia, Mohammad Hossein Boskabady","doi":"10.1080/03602532.2024.2442012","DOIUrl":null,"url":null,"abstract":"<p><p>Several studies indicate various pharmacological and therapeutic effects of peroxisome proliferator-activated receptors (PPARs) in different disorders. The current review describes the influences of PPARs on respiratory, allergic, and immunologic diseases. Various databases, including PubMed, Science Direct, and Scopus, were searched regarding the effect of PPARs on respiratory and allergic disorders from 1990 to 2024. The effects of PPARs stimulation on experimental animal models of respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), pulmonary fibrosis (PF), and lung infections were shown. Therapeutic potential mediated through PPARs has also been demonstrated in lung cancer, lung infections, and allergic and immunologic disorders. However, few clinical studies showed PPARs mediated therapeutic effects on asthma and COPD. The PPARs-mediated effects on various respiratory disorders were shown through antioxidant, immunomodulatory, anti-inflammatory, and other mechanisms. Therefore, this review indicated possible remedy effects mediated by these receptors in treating respiratory, allergic, and immunologic diseases. Moreover, this mechanistic review paves the way for researchers to consider further experimental and clinical studies.</p>","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":" ","pages":"26-50"},"PeriodicalIF":3.8000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Metabolism Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03602532.2024.2442012","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Several studies indicate various pharmacological and therapeutic effects of peroxisome proliferator-activated receptors (PPARs) in different disorders. The current review describes the influences of PPARs on respiratory, allergic, and immunologic diseases. Various databases, including PubMed, Science Direct, and Scopus, were searched regarding the effect of PPARs on respiratory and allergic disorders from 1990 to 2024. The effects of PPARs stimulation on experimental animal models of respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), pulmonary fibrosis (PF), and lung infections were shown. Therapeutic potential mediated through PPARs has also been demonstrated in lung cancer, lung infections, and allergic and immunologic disorders. However, few clinical studies showed PPARs mediated therapeutic effects on asthma and COPD. The PPARs-mediated effects on various respiratory disorders were shown through antioxidant, immunomodulatory, anti-inflammatory, and other mechanisms. Therefore, this review indicated possible remedy effects mediated by these receptors in treating respiratory, allergic, and immunologic diseases. Moreover, this mechanistic review paves the way for researchers to consider further experimental and clinical studies.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

过氧化物酶体增殖物激活受体在呼吸系统疾病中的重要作用

多项研究表明，过氧化物酶体增殖物激活受体（PPARs）在不同疾病中具有不同的药理和治疗作用。本文综述了ppar对呼吸道、过敏性和免疫疾病的影响。我们检索了PubMed、Science Direct和Scopus等多个数据库，以了解ppar在1990年至2024年间对呼吸系统和过敏性疾病的影响。研究了PPARs刺激对哮喘、慢性阻塞性肺疾病（COPD）、肺纤维化（PF）和肺部感染等呼吸系统疾病实验动物模型的影响。通过ppar介导的治疗潜力也已在肺癌、肺部感染、过敏和免疫疾病中得到证实。然而，很少有临床研究显示PPARs介导哮喘和COPD的治疗作用。ppars通过抗氧化、免疫调节、抗炎等机制介导多种呼吸系统疾病。因此，本文综述了这些受体在治疗呼吸道、过敏性和免疫性疾病中可能介导的治疗作用。此外，这一机制综述为研究人员考虑进一步的实验和临床研究铺平了道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Drug Metabolism Reviews 医学-药学

CiteScore

11.10

自引率

1.70%

发文量

审稿时长

1 months

期刊介绍： Drug Metabolism Reviews consistently provides critically needed reviews of an impressive array of drug metabolism research-covering established, new, and potential drugs; environmentally toxic chemicals; absorption; metabolism and excretion; and enzymology of all living species. Additionally, the journal offers new hypotheses of interest to diverse groups of medical professionals including pharmacologists, toxicologists, chemists, microbiologists, pharmacokineticists, immunologists, mass spectroscopists, as well as enzymologists working in xenobiotic biotransformation.